Last reviewed · How we verify
Topamax
At a glance
| Generic name | Topamax |
|---|---|
| Also known as | TPM, Topiramate |
| Sponsor | Ataturk University |
| Target | Nuclear receptor subfamily 1 group I member 2, Carbonic anhydrase 1, Carbonic anhydrase 12 |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
- Epilepsy characterized by intractable complex partial seizures
- Lennox-Gastaut syndrome
- Migraine Prevention
- Simple partial seizure
- Tonic-clonic epilepsy
Common side effects
- Paresthesia
- Weight loss
- Anorexia
- Speech disorders/related speech problems
- Dizziness
- Somnolence
- Nervousness
- Psychomotor slowing
- Abnormal vision
- Fatigue
- Fever
- Difficulty with memory
Key clinical trials
- Preoperative Weight Loss for Open Abdominal Wall Reconstruction (NA)
- Pharmacokinetics and Pharmacodynamics of Topiramate for Weight Loss in Youth: PHARMATOP (EARLY_PHASE1)
- Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study (PHASE4)
- Drug Therapy Induced Weight Loss to Improve Blood Vessel Function in Subjects With Obesity (PHASE2)
- Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder (PHASE4)
- Pharmacotherapy in Conjunction With Lifestyle Counseling for Management of Weight Regain After Bariatric Surgery (PHASE4)
- Neurophysiological Effects of Medication Tapering During Treatment With Spinal Cord Stimulation
- Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |